Cosmos Pharmaceutical Limited | DEPROZET Capsules
Cosmos Limited is one of the leading manufacturers of pharmaceutical products in Kenya and East Africa. Through our specialized Human Health and Animal Health.
Cosmos Limited,top pharmaceutical,top pharma,best pharma,best pharmaceutical,leading pharma,leading pharmaceutical,pharma,cosmos pharmaceutical,cosmos,cosmos Kenya,top pharmaceutical,best pharmaceutical,leading pharmaceutical,medicine,veterinary,animal health,human health,company,companies,manufacturer in Kenya,manufacturers in Kenya,Delvin Mugo,Mugo Delvin,manufacturers in east Africa,manufacturers in Africa ,Cosmos, cosmos pharmaceuticals,pharmaceuticals, pharmaceutical,pharmaceutical company in Kenya,pharmaceuticals companies in Kenya,pharmaceutical company in Nairobi, pharmaceuticals companies in Nairobi,pharmaceuticals companies Nairobi,Kenya pharmaceuticals companies,Nairobi pharmaceuticals,top pharma,best pharma,leading pharma,pharma,top pharmaceutical,best pharmaceutical,leading pharmaceutical,medicine,veterinary,animal health,human health,Kenya pharmaceutical,best medicine,Kenya best medicine,Nairobi manufacturer,best manufacturer,profitable company in Kenya,company,companies,manufacturer in Kenya,manufacturers in Kenya,manufacturers in east Africa,manufacturers in Africa,pharmacy in Kenya,pharmaceutical supplies in Kenya,pharmacies in Kenya,chemists in Kenya,chemist in Kenya,pharmaceutical companies in Kenya,leading pharmaceutical in Kenya, best pharmaceutical in Nairobi,best pharmaceutical in Kenya, pharmaceuticals companies Nairobi, pharmaceuticals companies Kenya, pharmaceuticals products distributor in Nairobi, pharmaceuticals products distributor in Kenya,Kenya Quality Healthcare Products, Quality Healthcare Products,A renown Pharmaceutical company in Kenya,A renown Pharmaceutical
page-template,page-template-full_width,page-template-full_width-php,page,page-id-17862,ajax_updown_fade,page_not_loaded,,side_area_uncovered_from_content,overlapping_content,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-theme-ver-13.6,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive



Prevention of the reuptake of monoamine transmitters such as serotonin, which potentiates their action in the brain, appears to be associated with antidepressant activity. SSRIs such as fluoxetine preferentially inhibit the reuptake of serotonin compared with noradrenaline, and have limited direct action at other neurotransmitter sites, including muscarinic receptors. They therefore cause fewer antimuscarinic or sedative side-effects than the tricyclic antidepressants and are less cardiotoxic.


Fluoxetine is readily absorbed from the gastrointestinal tract with peak plasma concentrations appearing about 6 to 8 hours after oral doses. Systemic bioavailability does not appear to be affected by food. Fluoxetine is extensively metabolised, by demethylation, in the liver to its primary active metabolite norfluoxetine. Excretion is mainly via the urine. Fluoxetine is widely distributed throughout the body. Fluoxetine has a relatively long elimination half-life of about 1 to 3 days after acute use and 4 to 6 days after long-term use; that of its metabolite, norfluoxetine, is even longer, being about 4 to 16 days. These long half-lives have clinical implications. Steady-state plasma concentrations will only be attained after several weeks. Additionally, fluoxetine and its metabolites may persist for a considerable time after treatment, and this has led to precautions concerning the subsequent use of other serotonergic drugs.
Fluoxetine and norfluoxetine are distributed into breast milk.


Deprozet® provides an alternative for the treatment of depression. It is also used as part of the management of obsessive compulsive disorders with or without agoraphobia, and as part of the management of bulimia nervosa. It is also used in the treatment of premenstrual dysphoric disorder.



In the treatment of depression: The usual dose of Deprozet® is 20mg daily in the morning gradually increased up to a maximum of 80mg daily (60mg in the elderly). Doses above 20mg a day may be administered in 2 divided doses.
In the management of bulimia nervosa: Doses of 60mg daily.
In the management of obsessive compulsive disorders: The initial dose is 20mg daily increased after several weeks if there is no response to up to 60mg daily.
Children: Not recommended.

Adverse Effects:

Adverse effects include dry mouth and gastro-intestinal disturbances such as nausea, vomiting, dyspepsia, constipation and diarrhoea, anorexia, and loss of weight may also occur. Neurological side effects include anxiety, restless, nervousness and insomnia or drowsiness and fatigue, headache, tremor, dizziness, convulsions, extrapyramidal effects and sexual dysfunction have also occurred. Excessive sweating and pruritus or skin rashes such as urticaria have also been reported.


Treatment involves emesis induction or gastric lavage followed by symptomatic and supportive therapy.


Although different antidepressants have been used together under expert supervision in refractory cases of depression, severe adverse reactions including the serotonin syndrome  may occur. Sequential prescribing of different types of antidepressant may also produce adverse reactions, and an appropriate drug-free interval should elapse between stopping one type of antidepressant and starting another. SSRIs should not generally be given to patients receiving MAOIs or for at least 2 weeks after their use. No treatment-free period is necessary after stopping a reversible inhibitor of monoamine oxidase type A (RIMA) and starting an SSRI. At least one week should elapse between withdrawing an SSRI and starting any drug liable to provoke a serious reaction (e.g. phenelzine). For fluoxetine the drug free interval is 5 weeks and may need to be further extended  if therapy has been prolonged or if high doses have been given.
Adverse effects such as the serotonin syndrome may also occur when the SSRIs are given with other drugs known to act on the same neurotransmitter, a consequence of synergistic interaction.


Store in a dry place below 25oC. Protect from light.  Keep all medicines out of the reach of children.

Prescription Only Medicine  (POM)
®Regd. TM                Ref. No: INS148/11.09

  • DEPROZET Capsules

    PresentationWhite, granular powder filled in green / yellow coloured hard gelatin capsule printed COSMOS / COSMOS on body and cap. Each capsule contains: Fluoxetine Hydrochloride BP equivalent to Fluoxetine 20mg. Pack size - 30's (3x10's)